Adimmune Corp Develops Vaccine for COVID-19|國光研發候選疫苗 台大試驗後證實有效
Taiwanese vaccine manufacturer Adimmune Corporation announced that company's candidate vaccine for the novel coronavirus has been proven effective in animal trials. The company hopes to start mass production by next winter when it passes human clinical trials.
As COVID-19 continues to threaten countries around the globe and seems to be lingering, the Taiwanese vaccine manufacturer Adimmune Corporation has successfully developed a candidate vaccine for the coronavirus after 4 months of hard work. It has been proven effective in the neutralization antibody assay conducted in the virology lab of the National Taiwan University.
We have picked the most deadly virus strain which is mainly found in Europe for the test. The test result showed the serum antibody in the vaccine can actually neutralize the virus and effectively suppress the virus. Therefore we are quite confident.
To develop this self-developed candidate vaccine, researchers used genetic sequencing and recombination to yield valid data, then conducted neutralization antibody assays in the lab. During these tests, mice injected with the vaccine had a stronger antibody reaction, producing a higher concentration of antibody to suppress the virus. When diluted, the antibody is still strong enough to prevent the virus from causing an infection. Adimmune estimates that it could begin the first phase of human clinical trials in the third quarter of 2020 after it obtains approval.
The reshuffled protein needs to be processed several times than the usual proteins before it can be injected into the human body. The work required is doubled with two layers of protection before it can be injected into the human body. Therefore the vaccine is more reliable and effective but more processing time is needed beforehand.
Adimmune stressed that it will collaborate with the National Health Research Institutes (NHRI) to start a challenge test to ensure the safety of the candidate vaccine. Its defect rate during the manufacturing process is also hard to predict. With that being said, the company is confident that the vaccine it produces will be sufficient for the 23 million people in Taiwan even in the worst case scenario. The company hopes to start mass production by next winter.
夜線／婦聯會未轉型政黨遭廢止 法院判暫停執行(7 小時前)
婦聯會未轉型政黨遭廢止 法院判暫停執行(7 小時前)